NASDAQ:BOLT Bolt Biotherapeutics Q2 2026 Earnings Results & Report $3.98 -0.30 (-7.01%) Closing price 03:55 PM EasternExtended Trading$4.03 +0.05 (+1.26%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bolt Biotherapeutics missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$4.57 versus the -$3.39 consensus estimate, while revenue of $0.01 million fell short of the $0.50 million estimate by $0.49 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 11, 2026TimeAfter Market ClosesConference Call4:00 PM ET Bolt Biotherapeutics EPS ResultsActual EPS-$4.57Consensus EPS -$3.39Beat/MissMissed by -$1.18One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersBolt Biotherapeutics Revenue ResultsActual Revenue$0.01 millionExpected Revenue$0.50 millionBeat/MissMissed by -$490.00 thousandYoY Revenue GrowthN/AUpcoming EarningsBolt Biotherapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Bolt Biotherapeutics Q2 2026 Earnings FAQ Did Bolt Biotherapeutics beat earnings estimates for Q2 2026? Bolt Biotherapeutics (NASDAQ:BOLT) reported earnings of -$4.57 per share for Q2 2026, missing the consensus estimate of -$3.39. The report was announced on Tuesday, August 11, 2026. What was Bolt Biotherapeutics' revenue for Q2 2026? Bolt Biotherapeutics reported revenue of $0.01 million for Q2 2026, against a consensus estimate of $0.50 million. When is Bolt Biotherapeutics' next earnings date? Bolt Biotherapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bolt Biotherapeutics on the company's earnings history page. Bolt Biotherapeutics Earnings HeadlinesBolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?October 7, 2026 | americanbankingnews.comBolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 11, 2026 | globenewswire.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 14 at 1:00 AM | Banyan Hill Publishing (Ad)Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateMarch 12, 2026 | globenewswire.comBolt Biotherapeutics to Participate in Upcoming March ConferencesFebruary 24, 2026 | globenewswire.comSee More Bolt Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bolt Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bolt Biotherapeutics and other key companies, straight to your email. Email Address About Bolt BiotherapeuticsBolt Biotherapeutics (NASDAQ:BOLT) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is based on its Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, which is designed to combine the tumor-targeting ability of antibodies with agents that activate the innate immune system. Bolt’s approach is intended to recruit and stimulate immune cells within the tumor microenvironment, potentially helping the body recognize and attack cancer cells. The company’s pipeline has included antibody-based immunotherapies directed at tumor-associated targets, including BDC-3042, an investigational Dectin-2 agonist designed to activate myeloid cells and enhance antitumor immune responses. Headquartered in Redwood City, California, Bolt Biotherapeutics was founded to advance new approaches to cancer treatment through immune-system activation. Its programs are being evaluated through clinical development and research activities, with the company’s work focused primarily on oncology applications.View Bolt Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
